302 related articles for article (PubMed ID: 28086927)
1. Can pegylated interferon improve the outcome of polycythemia vera patients?
Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
[TBL] [Abstract][Full Text] [Related]
2. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J; Kosiorek HE; Prchal JT; Rambaldi A; Berenzon D; Yacoub A; Harrison CN; McMullin MF; Vannucchi AM; Ewing J; O'Connell CL; Kiladjian JJ; Mead AJ; Winton EF; Leibowitz DS; De Stefano V; Arcasoy MO; Kessler CM; Catchatourian R; Rondelli D; Silver RT; Bacigalupo A; Nagler A; Kremyanskaya M; Levine MF; Arango Ossa JE; McGovern E; Sandy L; Salama ME; Najfeld V; Tripodi J; Farnoud N; Penson AV; Weinberg RS; Price L; Goldberg JD; Barbui T; Marchioli R; Tognoni G; Rampal RK; Mesa RA; Dueck AC; Hoffman R
Blood; 2022 May; 139(19):2931-2941. PubMed ID: 35007321
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Quintás-Cardama A; Kantarjian H; Manshouri T; Luthra R; Estrov Z; Pierce S; Richie MA; Borthakur G; Konopleva M; Cortes J; Verstovsek S
J Clin Oncol; 2009 Nov; 27(32):5418-24. PubMed ID: 19826111
[TBL] [Abstract][Full Text] [Related]
5. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
6. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
7. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Papaemmanuil E; Salama M; Singer-Weinberg R; Rampal R; Goldberg JD; Barbui T; Mesa R; Dueck AC; Hoffman R
Blood; 2019 Oct; 134(18):1498-1509. PubMed ID: 31515250
[TBL] [Abstract][Full Text] [Related]
9. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
10. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
Quintás-Cardama A; Abdel-Wahab O; Manshouri T; Kilpivaara O; Cortes J; Roupie AL; Zhang SJ; Harris D; Estrov Z; Kantarjian H; Levine RL; Verstovsek S
Blood; 2013 Aug; 122(6):893-901. PubMed ID: 23782935
[TBL] [Abstract][Full Text] [Related]
12. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
Nazha A; Khoury JD; Verstovsek S; Daver N
Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
[TBL] [Abstract][Full Text] [Related]
13. [Recent advances in polycythemia vera treatment].
Edahiro Y
Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
[TBL] [Abstract][Full Text] [Related]
14. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
Reiter A; Harrison C
Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for polycythemia vera.
Tibes R; Mesa RA
Expert Opin Emerg Drugs; 2013 Sep; 18(3):393-404. PubMed ID: 23968379
[TBL] [Abstract][Full Text] [Related]
16. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.
Larsen TS; Bjerrum OW; Pallisgaard N; Andersen MT; Møller MB; Hasselbalch HC
Ann Hematol; 2008 Oct; 87(10):847-50. PubMed ID: 18481066
[TBL] [Abstract][Full Text] [Related]
17. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.
Barbui T; Vannucchi AM; Finazzi G; Finazzi MC; Masciulli A; Carobbio A; Ghirardi A; Tognoni G
Am J Hematol; 2017 Nov; 92(11):1131-1136. PubMed ID: 28699191
[TBL] [Abstract][Full Text] [Related]
18. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
[TBL] [Abstract][Full Text] [Related]
19. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
[TBL] [Abstract][Full Text] [Related]
20. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
Them NC; Bagienski K; Berg T; Gisslinger B; Schalling M; Chen D; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Zagrijtschuk O; Klade C; Greil R; Gisslinger H; Kralovics R
Am J Hematol; 2015 Apr; 90(4):288-94. PubMed ID: 25545244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
